Skip to main content
CURLF
OTC Life Sciences

Curaleaf Goes Hostile with 45% Premium Bid for Aurora Cannabis

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
9
Price
$9.891
Mkt Cap
$2.619B
52W Low
$5.4
52W High
$15.15
52W Position info
83% above low
Off High info
35% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

CURLF sits 83% above its 52-week low of $5.4 on light trading volume (0.1× avg).

Summary

Curaleaf announced a hostile takeover bid for Aurora Cannabis, offering US$4.00 per share (45% premium) in stock and cash. The deal would create a global cannabis leader with over US$1.5B in revenue and US$40M in expected synergies.


Key Events · M&A and Partnerships · CURLF

  • Hostile Takeover Bid Announced

    Curaleaf intends to launch a take-over bid for all Aurora Cannabis shares at US$4.00 per share, comprising 0.3463 Curaleaf shares plus US$0.75 cash.

  • Premium to Aurora Shareholders

    The offer represents a 45% premium to Aurora's 30-day VWAP of US$2.75, and a 110% premium excluding Aurora's balance sheet cash.

  • Strategic Rationale

    Combines Aurora's EU-GMP cultivation capacity with Curaleaf's distribution platform; expected to generate at least US$40 million in annual cost synergies.

  • Pro Forma Scale

    Combined company would have over US$1.5 billion in LTM revenue, nearly US$350 million in LTM Adjusted EBITDA, and a pro forma market cap approaching US$3.0 billion.


Analysis · CURLF · Life Sciences

After private overtures were rebuffed, Curaleaf is taking its bid for Aurora Cannabis directly to shareholders. The offer values Aurora at US$4.00 per share—a 45% premium to its 30-day VWAP—through a mix of Curaleaf stock and cash. This transformative move would create a global cannabis leader with over US$1.5 billion in LTM revenue and nearly US$350 million in LTM Adjusted EBITDA. Because Aurora's board has refused to engage, the unsolicited bid bypasses management. Notably, the deal is not subject to financing or due diligence conditions, signaling Curaleaf's confidence, though execution risk remains given Aurora's resistance and potential defensive tactics.

At the time of this filing, CURLF was trading at $9.89 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CURLF - Latest Insights

CURLF
Aug 05, 2026, 10:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.35
Real-time Price: $9.89 info
Change: +$1.54 (+18%) info
Market Cap: $2.619B info
CURLF
Aug 05, 2026, 9:51 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.35
Real-time Price: $9.89 info
Change: +$1.54 (+18%) info
Market Cap: $2.619B info
CURLF
Aug 05, 2026, 9:43 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $8.35
Real-time Price: $9.89 info
Change: +$1.54 (+18%) info
Market Cap: $2.619B info
CURLF
Jul 14, 2026, 10:32 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.75
Real-time Price: $9.89 info
Change: +$0.1405 (+1%) info
Market Cap: $2.619B info
CURLF
Jun 26, 2026, 1:47 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.64
Real-time Price: $9.89 info
Change: +$6.25 (+172%) info
Market Cap: $2.619B info